U.S. Markets open in 9 hrs 15 mins
  • S&P Futures

    4,170.25
    -6.00 (-0.14%)
     
  • Dow Futures

    33,990.00
    -91.00 (-0.27%)
     
  • Nasdaq Futures

    14,042.25
    +12.75 (+0.09%)
     
  • Russell 2000 Futures

    2,259.00
    +3.30 (+0.15%)
     
  • Crude Oil

    62.91
    -0.22 (-0.35%)
     
  • Gold

    1,777.80
    -2.40 (-0.13%)
     
  • Silver

    25.85
    -0.25 (-0.96%)
     
  • EUR/USD

    1.1962
    -0.0019 (-0.1555%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3839
    -0.0001 (-0.0069%)
     
  • USD/JPY

    108.6430
    -0.1400 (-0.1287%)
     
  • BTC-USD

    57,109.08
    -2,121.29 (-3.58%)
     
  • CMC Crypto 200

    1,298.96
    -92.75 (-6.66%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,758.26
    +74.89 (+0.25%)
     

What Type Of Shareholders Make Up Cocrystal Pharma, Inc.'s (NASDAQ:COCP) Share Registry?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.

Every investor in Cocrystal Pharma, Inc. (NASDAQ:COCP) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

Cocrystal Pharma is not a large company by global standards. It has a market capitalization of US$145m, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about Cocrystal Pharma.

See our latest analysis for Cocrystal Pharma

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Cocrystal Pharma?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that Cocrystal Pharma does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Cocrystal Pharma's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

It would appear that 5.6% of Cocrystal Pharma shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Raymond Schinazi is currently the company's largest shareholder with 15% of shares outstanding. With 5.6% and 5.3% of the shares outstanding respectively, Renaissance Technologies Corp. and Phillip Frost are the second and third largest shareholders. Phillip Frost, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors. Furthermore, CEO Gary Wilcox is the owner of 0.8% of the company's shares.

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

Insider Ownership Of Cocrystal Pharma

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own a reasonable proportion of Cocrystal Pharma, Inc.. Insiders have a US$33m stake in this US$145m business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

General Public Ownership

The general public -- mostly retail investors -- own 51% of Cocrystal Pharma. This size of ownership gives retail investors collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions.

Private Equity Ownership

With an ownership of 5.0%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Public Company Ownership

We can see that public companies hold 3.8% of the Cocrystal Pharma shares on issue. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Cocrystal Pharma better, we need to consider many other factors. Case in point: We've spotted 4 warning signs for Cocrystal Pharma you should be aware of, and 1 of them is potentially serious.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.